Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Hydroxocobalamin
Drug ID BADD_D01099
Description Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency. It is also used in cyanide poisoning, Leber's optic atrophy, and toxic amblyopia.
Indications and Usage For treatment of pernicious anemia and the prevention and treatment of vitamin B12 deficiency arising from alcoholism, malabsorption, tapeworm infestation, celiac, hyperthyroidism, hepatic-biliary tract disease, persistent diarrhea, ileal resection, pancreatic cancer, renal disease, prolonged stress, vegan diets, macrobiotic diets or other restrictive diets. Also for the treatment of known or suspected cyanide poisoning.
Marketing Status approved
ATC Code B03BA03; V03AB33
DrugBank ID DB00200
KEGG ID D01027
MeSH ID D006879
PubChem ID 70678542
TTD Drug ID D0VF4H
NDC Product Code 50633-310; 51552-0158; 82298-921; 61281-9600; 40074-0011; 49452-3622; 11704-370; 58159-027; 0591-2888; 50396-7902; 49452-3623
UNII Q40X8H422O
Synonyms Hydroxocobalamin | Hydroxo-Cobalamin | Hydroxycobalamin
Chemical Information
Molecular Formula C62H90CoN13O15P-2
CAS Registry Number 13422-51-0
SMILES CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(= N6)C(=C7C(C(C(=N7)C=C8C(C(C(=N8)C(=C4[N-]5)C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C )CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.O.[Co]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrointestinal disorder07.11.01.001---
Haematochezia07.12.02.003; 24.07.02.012---
Headache17.14.01.001--
Heart rate increased13.14.04.002---
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.014051%
Hypokalaemia14.05.03.002--
Immune system disorder10.02.01.001---
Injection site reaction08.02.03.014; 12.07.03.015--
Irritability08.01.03.011; 19.04.02.013--
Lymphocyte count decreased13.01.06.006--
Malaise08.01.01.003--
Memory impairment17.03.02.003; 19.20.01.003--
Menopausal symptoms21.02.02.002---
Methaemoglobinaemia01.05.01.0020.027399%
Nausea07.01.07.001--
Nervous system disorder17.02.10.001---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Pain08.01.08.004--
Pleural effusion22.05.02.002--
Polycythaemia vera01.13.03.002; 16.21.03.003---
Pruritus23.03.12.001--
Pulmonary oedema02.05.02.003; 22.01.03.003--
Pyrexia08.05.02.0030.015456%
Rash23.03.13.001---
Restlessness17.02.05.021; 19.11.02.002--
Skin discolouration23.03.03.0050.007025%-
Skin disorder23.03.03.007---
Swelling08.01.03.015---
Tachycardia02.03.02.007---
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages